ClinicalTrials.gg
Active, not recruitingNCT07944664Updated Nov 18, 2026

A Phase 4, Single-arm, Interventional Study to Evaluate the Safety and Tolerability of Zolbetuximab Plus SOX as First-line Treatment of Chinese Participants With HER2-negative, Claudin (CLDN)18.2-Positive, La Unresectable or Metastatic GC/GEJC

A Phase 4 interventional study of zolbetuximab and S-1 in Gastric Cancer (GC) and Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by Rui-hua Xu, MD, PhD. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Rui-hua Xu, MD, PhD · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jan 2026, registered Nov 2026).
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 1,186 studies in Stomach Neoplasms with a site in China — 482 open to participants now, 559 under way, 50 of them phase 3. Stomach Neoplasms · China.

Planned enrollment
724th of 883
30 · median 87
Started
2026
with 94 others
Phase 4
25 of 1,186
6 open now
Primary completion
2028-08
later than 485 of 558 live
Registered
1,184th of 1,186
by date

Among the 1,186 studies in Stomach Neoplasms with a site in China, this one is the 724th largest by planned enrollment of the 883 interventional ones that give a count, is one of 95 that started in 2026, is one of 25 in phase 4, reaches primary completion later than 485 of the 558 other live ones, and was the 1,184th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

482 of the 1,186 studies in Stomach Neoplasms with a site in China are open now. Recruiting first, the newest first:

477 more — sign in →

All 482 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,186 studies in Stomach Neoplasms with a site in China, or all of them as a file.
02

Study summary

Following the approval of zolbetuximab in China, physicians can use zolbetuximab plus fluoropyrimidine- and platinum-containing chemotherapy to treat HER2-negative, CLDN18.2 positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, as indicated in the label. A quantitative survey conducted by Astellas in China was completed by 100 Chinese HCPs, based on which SOX emerged as the most frequently used chemotherapy regimen for this indication (data on file). However, safety and efficacy data for zolbetuximab plus SOX are limited. This study aims to assess the safety and tolerability of zolbetuximab plus SOX as the first-line treatment of participants with HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Read the detailed description
  1. Background Patients with gastric or GEJ adenocarcinomas have a high and ongoing unmet medical need. Patients with gastric cancer in China account for approximately 37% of the global gastric cancer population, and the majority are diagnosed with advanced gastric cancer (only approximately 20% of patients are diagnosed with early gastric cancer). Patients who seek medical consult already have locally advanced or distant metastatic disease and have lost their opportunity for surgical resection. The 5-year survival rate of metastatic gastric cancer is only 9.4%.

    Two phase 3 studies (SPOTLIGHT and GLOW) demonstrated that zolbetuximab plus chemotherapy significantly improved the PFS and OS of participants with HER2-negative, CLDN18.2 positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma compared to chemotherapy alone, which supported its regulatory approval in many countries.

    Following the approval of zolbetuximab in China, physicians can use zolbetuximab plus fluoropyrimidine- and platinum-containing chemotherapy to treat HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma, as indicated in the label. A quantitative survey conducted by Astellas in China was completed by 100 Chinese HCPs, based on which SOX emerged as the most frequently used chemotherapy regimen (in approximately 40% of patients, as estimated by the HCPs) in the first-line treatment of HER2-negative advanced gastric/GEJ adenocarcinoma, either as chemotherapy alone or as chemotherapy combined with checkpoint inhibitors (data on file). This is further supported by the fact that the standard of care for unresectable or metastatic gastric or GEJ adenocarcinoma in Asia consists of a doublet regimen of S-1 or capecitabine plus cisplatin or oxaliplatin.

    Safety and efficacy data for zolbetuximab plus SOX are limited. This study aims to assess the safety and tolerability of zolbetuximab plus SOX as the first-line treatment of participants with HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

  2. Study design overview This is a phase 4, single-arm, interventional study to evaluate the safety and tolerability of zolbetuximab plus SOX as first-line treatment in Chinese participants with HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

    Participant eligibility (including CLDN18.2-positive status) will be confirmed during the 45-day Screening Period. Eligible participants will be treated with zolbetuximab on D1 of each cycle until the participant meets study treatment discontinuation criteria. For all study treatments, a cycle is defined as approximately 21 days. Participants will also receive up to 6 cycles of SOX treatment. Oxaliplatin will be administered on D1 of each cycle, whereas S-1 will be taken twice daily on Days 1 through 14. After a maximum of 6 cycles of SOX, oxaliplatin will be discontinued; participants may continue to receive S-1 twice daily on Days 1 through 14 of each cycle at the investigator's discretion until the participant meets study treatment discontinuation criteria.

  3. Risk/Beneifit assessment Zolbetuximab is approved for use in combination with fluoropyrimidine- and platinum-containing chemotherapy for the treatment of HER2-negative, CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Based on currently available clinical data, there is potential of achieving clinically relevant benefit in combination with oxaliplatin and fluoropyrimidine-containing chemotherapy in a first-line setting and as a single agent in the later line setting.

Based on currently available clinical data, zolbetuximab was tolerated from a safety perspective and most observed AEs have been considered manageable. Nonclinical toxicity data were supportive of clinical findings.

Important identified risks are hypersensitivity reactions and IRRs. There are no important potential risks or missing information.

Participants receiving zolbetuximab do not need to be premedicated for prevention of hypersensitivity reactions and IRRs; however, participants should be closely monitored for infusion related reactions to facilitate early identification and management.

Overall, the risks associated with zolbetuximab in combination with SOX are balanced by the anticipated benefits to patients with HER2-negative CLDN18.2-positive, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma in a first-line setting.

03

Conditions studied

  • Gastric Cancer (GC)
  • Gastroesophageal Junction (GEJ) Adenocarcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥ 18 and \< 75 years of age) of Chinese origin residing in Mainland China at the time of signing the .
  2. confirmed diagnosis of gastric or GEJ adenocarcinoma.
  3. Radiologically confirmed locally advanced unresectable or disease within 28 days prior to first dose of the study treatment.
  4. Radiologically evaluable disease (measurable and/or non-measurable) according to 1.1, per local assessment, ≤ 28 days prior to first dose of the study treatment. For a participant with only 1 evaluable lesion and prior radiotherapy ≤ 3 months before enrollment, the lesion must either be outside the field of prior radiotherapy or have documented progression following radiation therapy.
  5. -negative tumor as determined by local testing on a gastric or GEJ tumor specimen.
  6. CLDN18.2 expression in ≥ 75% of tumor cells demonstrating moderate to strong membranous staining as determined by central IHC testing.
  7. performance status 0 or 1.
  8. Predicted ≥ 12 weeks in the opinion of the investigator.
  9. A participant must meet all of the following criteria based on locally analyzed laboratory tests collected within 14 days prior to enrollment. In the case of multiple sample collections within this period, the most recent sample collection with available results should be used to determine eligibility.

    1. ≥ 9 g/dL. A participant requiring transfusions is eligible if they have a posttransfusion Hgb ≥ 9 g/dL.
    2. ≥ 1.5 x 109/L.
    3. ≥ 100 x 109/L.
    4. Albumin ≥ 2.5 g/dL.
    5. TBL ≤ 1.5 x without liver metastases (or \< 3.0 x ULN if liver metastases are present).
    6. and ALT ≤ 2.5 x ULN without liver metastases (or ≤ 5 x ULN if liver metastases are present).
    7. Estimated ≥ 30 mL/min.
    8. and PTT ≤ 1.5 x ULN (except for a participant receiving anticoagulation therapy).
  10. A female participant is eligible to participate if she is not pregnant (negative serum pregnancy test at Screening; a female participant with elevated serum beta human chorionic gonadotropin and a demonstrated non-pregnant status through additional testing is eligible) and at least 1 of the following conditions applies:

    1. Not a as defined in [Section 10.2 Requirements] OR
    2. WOCBP who agrees to follow the contraceptive guidance as defined in [Section 10.2 Contraception Requirements] throughout the treatment period and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study treatment.
  11. A female participant must agree not to breastfeed starting at Screening and throughout the study period and for 6 months after the final study treatment administration.
  12. A female participant must not donate ova starting at Screening and throughout the study period and for 9 months after the final administration of oxaliplatin and 6 months after the final administration of all other study treatment.
  13. A sexually active male participant with female partner(s) who are of childbearing potential must agree to use contraception as detailed in [Section 10.2 Contraception Requirements] during the treatment period and for at least 6 months after the final study treatment administration.
  14. A male participant must not donate sperm starting at Screening and throughout the study period and for 6 months after the final study treatment administration.
  15. A male participant with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or for the time partner is breastfeeding throughout the study period and for 6 months after the final study treatment administration.
  16. IRB/IEC approved written informed consent must be obtained from the participant or LAR prior to any study-related procedures.
  17. Participant agrees not to participate in another interventional study while receiving study treatment in the present study.

Exclusion criteria

Exclusion Criteria:

  1. Prior severe allergic reaction or intolerance to known ingredients of zolbetuximab or other monoclonal antibodies, including humanized or chimeric antibodies.
  2. Known immediate or delayed , intolerance or to any component of study treatment.
  3. Prior severe allergic reaction or intolerance to S-1 or oxaliplatin.
  4. Complete gastric outlet syndrome or a partial gastric outlet syndrome with persistent/recurrent vomiting.
  5. Significant gastric bleeding and/or untreated gastric ulcers, per investigator's judgment.
  6. Known history of a positive test for infection or known active HB (HBs Ag positive) or C infection.

    1. For a participant who is HBs Ag negative, but HBc Ab positive, an HB DNA test will be performed, and if positive, the participant will be excluded.
    2. A participant with positive serology but negative HCV RNA test is eligible.
    3. A participant treated for HCV with undetectable viral load results is eligible.
  7. Active disease that has required systemic treatment within the past 3 months prior to Screening.
  8. Active infection requiring systemic therapy that has not completely resolved within 7 days prior to Screening.
  9. Significant cardiovascular disease, including any of the following:

    1. Congestive heart failure (defined as Class III or IV), myocardial infarction, unstable angina, coronary angioplasty, coronary stenting, coronary artery bypass graft, cerebrovascular accident or hypertensive crisis within 6 months prior to Screening.
    2. History of ventricular arrhythmias (i.e., sustained ventricular tachycardia, ventricular fibrillation or Torsades de Pointes).
    3. > 450 msec for a male participant; QTc interval > 470 msec for a female participant.
    4. History or family history of congenital long QT syndrome.
    5. Cardiac arrhythmias requiring anti-arrhythmic medications (a participant with rate controlled atrial fibrillation for > 1 month prior to Screening is eligible).
  10. History of central nervous system and/or carcinomatous meningitis from gastric/GEJ cancer.
  11. Known peripheral sensory neuropathy > grade 1 unless the absence of deep tendon reflexes is the sole neurological abnormality.
  12. Major surgical procedure ≤ 28 days prior to Screening.

    a. Participant without complete recovery from a major surgical procedure ≤ 14 days prior to Screening.

  13. Psychiatric illness or social situations that would preclude study compliance, per investigator judgment.
  14. Another for which treatment is required per investigator's clinical judgment.

    Prior/Concomitant Therapy

  15. Received prior systemic chemotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma. However, participant may have received either or adjuvant chemotherapy, immunotherapy or other systemic anticancer therapies as long as it was completed at least 6 months prior to Screening. The participant may have received treatment with herbal medications that have known antitumor activity > 28 days prior to Screening.
  16. Received radiotherapy for locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma ≤ 14 days prior to Screening and has not recovered from any related toxicity.
  17. Received systemic therapy, including systemic within 14 days prior to Screening. A participant using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone or up to 10 mg per day of prednisone), receiving a single dose of systemic corticosteroids or receiving systemic corticosteroids as premedication for radiologic imaging contrast use is eligible.
  18. Received any other agents or devices within 28 days prior to Screening.
  19. Initiated with zolbetuximab plus SOX as the treatment for advanced or recurrent gastric cancer at a site other than the study site.

    Other Exclusion Criteria

  20. Any concurrent disease, infection or co-morbid condition that interferes with the ability of the participant to participate in the study, which places the participant at undue risk or complicates the interpretation of data in the opinion of the investigator.
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental

    Zolbetuximab + S-1+Oxaliplatin

    Drug: zolbetuximab · Drug: S-1 · Drug: Oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment.

    Safety

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. PFS

    PFS, defined as the time from the date of first dose of the study treatment until the date of radiological disease progression (per RECIST 1.1 by investigator) or death from any cause, whichever is earliest

    Time frame: study treatment until the date of radiological disease progression (per RECIST 1.1 by investigator) or death from any cause,up to 18 months

  2. ORR

    ORR, defined as the proportion of participants who have a BOR of CR or PR (per RECIST 1.1 by investigator)

    Time frame: through study completion, an average of 1 year

  3. DOR

    DOR, defined as the time from the date of the first response (CR or PR) until the date of radiological disease progression (per RECIST 1.1 by investigator) or death from any cause, whichever is earliest

    Time frame: through study completion, an average of 1 year

Other outcomes

  1. To evaluate the expression of PD-L1 and CLDN18.2 before and after treatment with zolbetuximab plus SOX

    For PD-L1, change in the CPS (reported as a percentage) from baseline (i.e., pre-treatment) to the time of disease progression For CLDN18.2, change in CLDN18.2 expression level (reported as a percentage) from baseline (i.e., pre-treatment) to the time of disease progression

    Time frame: study treatment until the date of radiological disease progression (per RECIST 1.1 by investigator) or death from any cause,up to 18 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Aug 2028, 31 months after the start.

Of 28 phase 4 interventional studies under Stomach Neoplasms, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 17. This study's planned 31 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2026
First posted
Nov 18, 2026
StartActual
Jan 13, 2026
Primary completionEst.
Aug 2028
CompletionEst.
Dec 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944664
Lead sponsor
Rui-hua Xu, MD, PhD
Responsible party
Rui-hua Xu, MD, PhD (MD,PhD,Principal Investigator, Sun Yat-sen University) — Sponsor-investigator
First posted
Nov 18, 2026
Start date
Jan 13, 2026
Primary completion
Aug 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolbetuximab

Start the discussion